First, CLL patients from the validation cohort with clear genotypic characteristics, that is, TP53/ATM WT (WT; n=27), biallelic TP53 defects (n=6) or biallelic ATM defects (n=9) (i.e., mutation+deletion) were evaluated. This evidence concerns the gene ATM and B-cell chronic lymphocytic leukemia.